News & Publications - Page 3 of 9

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting

  • KemPharm and Corium Expand Relationship with New Consultation Services Agreement

  • KemPharm Files Preliminary Proxy for Special Meeting of Stockholders

  • KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies

  • KemPharm to Present at Upcoming September Investor Conferences

  • KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA

  • KemPharm Reports Second Quarter 2020 Financial Results

  • KemPharm to Report Second Quarter 2020 Financial Results

  • KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484

  • KemPharm Issues Letter to Shareholders

  • KemPharm Receives Day-74 Letter for KP415 NDA

  • KemPharm Reports First Quarter 2020 Financial Results